IC
FATE icon

Ikarian Capital’s Fate Therapeutics FATE Stock Holding History

Ikarian Capital’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100,000
Closed -$5.93M – 209
2021
Q3 		$5.93M Hold
100,000
– – 0.42% 58
2021
Q2 		$8.68M Sell
100,000
-8,900
-8% -$717K 0.7% 40
2021
Q1 		$8.98M Buy
108,900
+70,100
+181% +$6.72M 0.3% 76
2020
Q4 		$3.53M Sell
38,800
-11,300
-23% -$702K 0.16% 115
2020
Q3 		$2M Hold
50,100
– – 0.15% 112
2020
Q2 		$1.72M Hold
50,100
– – 0.14% 111
2020
Q1 		$1.11M Buy
+50,100
New +$1.27M 0.08% 119

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Ikarian Capital's FATE Position: Q2 2022 in Review

Ikarian Capital sold out of Fate Therapeutics (FATE) in Q2 2022, closing a stake of 9,640 shares — an estimated $374K sold.

Ikarian Capital first reported a position in FATE in Q1 2021 and held it in 4 quarters. The position peaked at $528K in Q4 2021. 233 funds tracked by Wall St. Rank hold FATE as of Q2 2022.

  • Ikarian Capital reported no remaining Fate Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Ikarian Capital sold 9,640 Fate Therapeutics shares in Q2 2022, an estimated $374K.
  • Ikarian Capital first reported a position in Fate Therapeutics in Q1 2021 and held it in 4 quarters.
  • Ikarian Capital's Fate Therapeutics position peaked at $528K in Q4 2021.
  • 233 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.